Literature DB >> 18327640

Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic.

Leo Bastiaens1.   

Abstract

OBJECTIVE: To evaluate change in quality of life in a community clinic ADHD population treated with atomoxetine or stimulants. No direct comparisons between atomoxetine and stimulants to improve quality of life in ADHD are available.
METHODS: A prospective, nonrandomized comparison between ADHD patients treated with atomoxetine or stimulants in one clinic. Structured diagnostic assessment tools and a specific quality of life measure were used.
RESULTS: 84 patients (atomoxetine n = 39/stimulants n = 45), between the ages of 5 and 18, were treated for approximately 8 months. At end point, there were no significant differences in improvements of quality of life between the two groups. Age, participation in psychotherapy, and parental disability were not correlated with quality of life changes. Patients with lower baseline scores improved most.
CONCLUSIONS: Both atomoxetine and stimulants led to a modest increase in quality of life in this community clinic ADHD population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327640     DOI: 10.1007/s11126-008-9070-6

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  8 in total

1.  Effectiveness and tolerability of atomoxetine in a real-world ADHD population: nonrandomized comparison with stimulants.

Authors:  Leo Bastiaens
Journal:  Psychiatry (Edgmont)       Date:  2007-12

2.  Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children.

Authors:  Rodrigo Escobar; Cesar A Soutullo; Amaia Hervas; Xavier Gastaminza; Pepa Polavieja; Inmaculada Gilaberte
Journal:  Pediatrics       Date:  2005-09       Impact factor: 7.124

3.  Pediatric psychopharmacology in a capitated managed care system: how do patients fare?

Authors:  L Bastiaens
Journal:  J Child Adolesc Psychopharmacol       Date:  1998       Impact factor: 2.576

4.  Quality of life of children and adolescents: during psychiatric treatment in a community mental health setting.

Authors:  Leo Bastiaens; Cathy Dello Stritto
Journal:  Psychiatry (Edgmont)       Date:  2005-08

5.  Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.

Authors:  Anne F Klassen; Anton Miller; Stuart Fine
Journal:  Pediatrics       Date:  2004-11       Impact factor: 7.124

6.  Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.

Authors:  Daniel Geller; Craig Donnelly; Frank Lopez; Richard Rubin; Jeffrey Newcorn; Virginia Sutton; Rosalie Bakken; Martin Paczkowski; Douglas Kelsey; Calvin Sumner
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2007-09       Impact factor: 8.829

7.  A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

Authors:  Suyash Prasad; Val Harpin; Lynne Poole; Harry Zeitlin; Saroj Jamdar; Kanagasabai Puvanendran
Journal:  Curr Med Res Opin       Date:  2007-02       Impact factor: 2.580

8.  Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine.

Authors:  Amy R Perwien; Douglas E Faries; Christopher J Kratochvil; Calvin R Sumner; Douglas K Kelsey; Albert J Allen
Journal:  J Dev Behav Pediatr       Date:  2004-08       Impact factor: 2.225

  8 in total
  4 in total

Review 1.  Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.

Authors:  Yu-Shu Huang; Ming-Horng Tsai
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

2.  Improvement in global psychopathology increases quality of life during treatment of ADHD with atomoxetine or stimulants.

Authors:  Leo Bastiaens
Journal:  Psychiatr Q       Date:  2011-12

3.  Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials.

Authors:  Peter M Wehmeier; Alexander Schacht; Rodrigo Escobar; Nicola Savill; Val Harpin
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2010-12-06       Impact factor: 3.033

4.  Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

Authors:  Oscar G Bukstein; L Eugene Arnold; Jeanne M Landgraf; Paul Hodgkins
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-12-10       Impact factor: 3.033

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.